{"id":"docetaxel-cyclophosphamide-capecitabine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"10-30","effect":"Mucositis"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"50-80","effect":"Alopecia"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that stabilizes microtubules and prevents cell division. Cyclophosphamide is an alkylating agent that cross-links DNA and prevents replication. Capecitabine is a fluoropyrimidine that inhibits thymidylate synthase and is incorporated into DNA/RNA. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and induce cell death through different mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:43.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely early-stage or metastatic, based on typical use of this combination)"}]},"trialDetails":[{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00544765","phase":"PHASE3","title":"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-09","conditions":"Breast Cancer","enrollment":2014},{"nctId":"NCT01869192","phase":"PHASE2","title":"Phase II Trial for Large ER-Negative Breast Cancers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2003-03-05","conditions":"Malignant Neoplasm of Female Breast","enrollment":72},{"nctId":"NCT03507465","phase":"PHASE2, PHASE3","title":"Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-11-29","conditions":"Breast Cancer","enrollment":290},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT02846428","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT02115152","phase":"PHASE2","title":"Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2014-06","conditions":"Stage II Breast Cancer, Stage III Breast Cancer","enrollment":100},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT00288002","phase":"PHASE3","title":"Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2005-01","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00005908","phase":"PHASE2","title":"Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60},{"nctId":"NCT00830544","phase":"PHASE2","title":"Study of Neoadjuvant Chemotherapy of Breast Cancer","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00050167","phase":"PHASE1","title":"Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Breast Cancer","enrollment":603},{"nctId":"NCT00352378","phase":"PHASE3","title":"Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2002-06","conditions":"Breast Cancer","enrollment":209},{"nctId":"NCT00114816","phase":"PHASE3","title":"Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer","status":"COMPLETED","sponsor":"Finnish Breast Cancer Group","startDate":"2004-01","conditions":"Breast Cancer","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel, Cyclophosphamide, Capecitabine","genericName":"Docetaxel, Cyclophosphamide, Capecitabine","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and induce cell death through different mechanisms. Used for Breast cancer (likely early-stage or metastatic, based on typical use of this combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}